Login / Signup

Effect of intravenous alteplase on post-stroke depression in the WAKE UP trial.

Alina KönigsbergSusanne SehnerSönke ArltBastian ChengClaus Z SimonsenFlorent BoutitieJoaquin SerenaVincent ThijsMartin EbingerMatthias EndresJochen B FiebachRobin LemmensKeith W MuirNorbert NighoghossianSalvador PedrazaChristian GerloffGötz Thomallanull null
Published in: European journal of neurology (2021)
Treatment with alteplase in patients with acute stroke resulted in lower rates of depression at 90 days, which were only partially explained by reduced functional disability. Predictors of PSD including history and clinical characteristics may help in identifying patients at risk of PSD.
Keyphrases
  • depressive symptoms
  • acute ischemic stroke
  • sleep quality
  • multiple sclerosis
  • clinical trial
  • study protocol
  • high dose
  • phase iii
  • phase ii
  • combination therapy
  • low dose